
    
      This is a multicenter, randomized, double-blind and placebo-controlled study. The
      investigational drug is HBM9161 injection, and the indication is MG.

      The subjects will be randomized to three dose groups (340mg, 680mg and placebo) for a 6
      weeks' double-blind treatment period followed by an open-label extension treatment period.
      The study will investigate the safety, efficacy and pharmacodynamic and pharmacokinetic of
      HBM9161 in patients with attack of MG in China.
    
  